179 related articles for article (PubMed ID: 10361552)
21. PSA as a treatment marker for prostate cancer?
Miller M
J Natl Cancer Inst; 1999 Jul; 91(13):1108-10. PubMed ID: 10393715
[No Abstract] [Full Text] [Related]
22. PSA relapse prostate cancer: the importance of tailored therapy.
Aranha O; Vaishampayan U
Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen doubling time as a prognostic marker in prostate cancer.
Eastham JA
Nat Clin Pract Urol; 2005 Oct; 2(10):482-91. PubMed ID: 16474622
[TBL] [Abstract][Full Text] [Related]
24. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
[TBL] [Abstract][Full Text] [Related]
25. How to use prostate-specific antigen.
Ploch NR; Brawer MK
Urology; 1994 Feb; 43(2 Suppl):27-35. PubMed ID: 7509534
[TBL] [Abstract][Full Text] [Related]
26. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.
D'Amico AV; Moul J; Carroll PR; Sun L; Lubeck D; Chen MH
J Urol; 2005 May; 173(5):1572-6. PubMed ID: 15821488
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen (PSA) in the management of 500 prostatic patients.
Guillet J; Role C; Duc AT; François H
Am J Clin Oncol; 1988; 11 Suppl 2():S61-2. PubMed ID: 2468274
[TBL] [Abstract][Full Text] [Related]
28. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
D'Amico AV; Moul JW; Carroll PR; Cote K; Sun L; Lubeck D; Renshaw AA; Loffredo M; Chen MH
J Natl Cancer Inst; 2004 Apr; 96(7):509-15. PubMed ID: 15069112
[TBL] [Abstract][Full Text] [Related]
29. Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).
Collette L; de Reijke TM; Schröder FH;
Eur Urol; 2003 Aug; 44(2):182-9; discussion 189. PubMed ID: 12875936
[TBL] [Abstract][Full Text] [Related]
30. [PSA progression under hormone therapy - of prognostic relevance?].
Miller K
Aktuelle Urol; 2012 Jul; 43(4):262-4. PubMed ID: 22869497
[TBL] [Abstract][Full Text] [Related]
31. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
[TBL] [Abstract][Full Text] [Related]
32. Cytokine variations in patients with hormone treated prostate cancer.
Wise GJ; Marella VK; Talluri G; Shirazian D
J Urol; 2000 Sep; 164(3 Pt 1):722-5. PubMed ID: 10953133
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.
Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
J Clin Oncol; 1995 Dec; 13(12):2944-53. PubMed ID: 8523059
[TBL] [Abstract][Full Text] [Related]
35. Current biomarkers for diagnosing of prostate cancer.
Stephan C; Jung K; Ralla B
Future Oncol; 2015; 11(20):2743-55. PubMed ID: 26358139
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen as a marker of disease activity in prostate cancer.
Partin AW; Hanks GE; Klein EA; Moul JW; Nelson WG; Scher HI
Oncology (Williston Park); 2002 Sep; 16(9):1218-24; discussion 1224, 1227-8 passim. PubMed ID: 12380948
[TBL] [Abstract][Full Text] [Related]
37. The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer.
Smith DC; Pienta KJ
Urol Clin North Am; 1997 May; 24(2):433-7. PubMed ID: 9126241
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen screening: pro.
Loeb S; Catalona WJ
Curr Opin Urol; 2010 May; 20(3):185-8. PubMed ID: 20224413
[TBL] [Abstract][Full Text] [Related]
39. Does failure of single hormone therapy delineate hormone refractoriness for prostate cancer?
Kotwal S; Whelan P
Scand J Urol Nephrol; 2008; 42(2):116-20. PubMed ID: 17907049
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone.
Morioka M; Kobayashi T; Furukawa Y; Jo Y; Shinkai M; Matsuki T; Yamamoto T; Tanaka H
Urol Int; 2002; 68(1):10-5. PubMed ID: 11803262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
